Author: admin

View eBook Sexually transmitted infections (STIs), often also referred to as sexually transmitted diseases (STDs), remain one of the most preventable and treatable global health challenges. The World Health Organization (WHO) has set an ambitious target: to eliminate key STIs—including syphilis, gonorrhea, chlamydia and trichomoniasis—as public health threats by 2030. Achieving this vision requires not only effective treatment, but also widespread access to accurate, timely and convenient diagnostics. The STI diagnostics market is expanding quickly in response to these needs. Rising infection rates after the COVID-19 pandemic, together with greater awareness of sexual health and advances in molecular technologies, are…

Credit: gorodenkoff / iStock / Getty Images Plus Researchers at the University of Colorado Anschutz have developed a method to predict how patients with traumatic injury will recover, the amount of time they will spend in intensive care, and the likelihood of complications such as organ failure by analyzing blood biomarkers. Published today in Science Translational Medicine, their findings provide unprecedented insights into why patients with similar injuries can sometimes have vastly different outcomes and recovery paths. “This is precision medicine for trauma,” said Kirk Hansen, PhD, professor of biochemistry at CU Anschutz and a senior author of the study.…

Credit: Sanjeri/Getty Images CiteAb launched the CiteAb Explore Platform, comprising its reagent search engine with its new image search engine. According to CiteAb, its database contains 16M+ research tools and their use in 40M+ publications, covering antibodies, proteins, models, and kits. This data underpins the Explore Platform, which helps researchers identify fit-for-purpose reagents, faster, says Andrew Chalmers, PhD, CEO. The new image search tool allows researchers to investigate peer-reviewed scientific images. Developed with input from the scientific community, it provides access to 850,000+ cropped experimental images—covering 610,000+ proteins, 5,000+ diseases, and 160,000 cell lines—linked directly to publications and the reagents…

Credit: Juan Gaertner / Science Photo Library / Getty Images In autoimmunity and immune-mediated disorders, fields long dominated by chronic immunosuppression and symptom management, Tr1X Bio (pronounced “Tricks Bio”) bet big on long-term immune tolerance powered by regulatory T (Treg) cell therapy that can be mass-produced, and it appears that their strategy has paid off. At the 2026 ASTCT/CIBMTR Tandem Meetings, Tr1X presented first-in-human clinical data for TRX103, an allogeneic, off-the-shelf type 1 regulatory T cell (Tr1) therapy, a Treg subtype important for immune tolerance dampening, marking what it says is the first clinical proof of biology for this cell…

Automation—and the SLAS meeting dedicated to it—continues to grow bigger and more exciting each year. Reporting from the meeting in Boston, Julianna LeMieux, PhD, and Uduak Thomas are soaking in the science and technology. Stepping away briefly from sessions, the expo floor, and coffee breaks, they share highlights from the meeting, including the keynote address, an omics session, major news and conversations from the meeting, and their top takeaways (cold weather included).

Cross section showing human oesophageal cancer, computer illustration. Researchers at Case Western Reserve University have discovered genetic mutations in a gene that place people at higher risk of developing Barret’s esophagus, a condition that greatly increases the risk of developing esophageal adenocarcinoma. The study, published in Nature Communications, found that the gene VSIG10L is a regulator of esophageal homeostasis and that mutations in this gene can weaken the esophageal lining and increase susceptibility to Barrett’s esophagus (BE) via a mechanism linking impaired epithelial maturation to bile acid-induced injury. “We found that this gene acts like a quality control system for…

age1 leads Series C as Loyal advances LOY-002 toward FDA approval, completing key requirements for conditional approval. Loyal, the clinical-stage animal health company developing what it hopes will become the first FDA-approved drug for lifespan extension, has raised $100 million in a Series C financing led by age1, the next generation of Laura Deming’s Longevity Fund. Baillie Gifford participated alongside existing investors. The raise follows a year in which the company completed two of the three major technical requirements for FDA Expanded Conditional Approval for its lead program, LOY-002, and finished enrollment of STAY, its pivotal efficacy trial involving more…

Amyloid plaques are misfolded proteins aggregates between neurons, Alzheimer’s disease illustration. [Artur Plawgo/Getty Images] Scientists have long known Alzheimer’s disease (AD) involves the build up of toxic amyloid-β (Aβ) peptides in the brain but have struggled to understand how these harmful protein fragments are produced. An international research team headed by scientists at Northwestern University has now pinpointed when and where toxic proteins accumulate within the brains of Alzheimer’s disease patients, and discovered that a decades-old FDA-approved anti-epileptic drug can stop the accumulation process before it even begins. Studying animal models, human neurons and brain tissue from high-risk patients, the…

Credit: Nicola Tree / Getty Images DNA barcoding can reflect the complex cellular makeup of cancerous tumors, according to a study that could help drive the development of precision oncology. The findings, in Molecular Systems Biology, indicated that, while both solid biopsies and those from blood samples broadly represented composition, results varied between tumors. This suggests that combining both strategies could provide a more accurate representation of disease. “DNA barcoding enabled us to investigate entire tumors, solid biopsies and even liquid biopsies. We were then able to accurately quantify how much tumor heterogeneity is captured in biopsies,” explained senior researcher…

NHS primary care data joins UK Biobank for 500,000 volunteers, making early risk, multimorbidity and prevention easier to study. The UK government has granted UK Biobank access to coded general practice data for its 500,000 volunteers in England, marking a significant expansion of one of the world’s most intensively characterized biomedical cohorts [1]. The move, enabled by a data provision notice published on 10 February 2026, allows primary care records – including diagnoses, prescriptions, referrals and laboratory results – to be linked within UK Biobank’s secure research environment. GP-linked feeds have included Scotland and Wales; the new step is coherent…